TY - JOUR
T1 - Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection
T2 - statement from a working group of thoracic pathologists
AU - Kerr, Keith M.
AU - Bubendorf, Lukas
AU - Lopez-Rios, Fernando
AU - Khalil, Farah
AU - Roy-Chowdhuri, Sinchita
AU - Joubert, Philippe
AU - Hartmann, Arndt
AU - Guerini-Rocco, Elena
AU - Yatabe, Yasushi
AU - Hofman, Paul
AU - Cooper, Wendy A.
AU - Dacic, Sanja
PY - 2024/2
Y1 - 2024/2
N2 - Many patients with non-small cell lung cancer do not receive guideline-recommended, biomarker-directed therapy, despite the potential for improved clinical outcomes. Access to timely, accurate, and comprehensive molecular profiling, including targetable protein overexpression, is essential to allow fully informed treatment decisions to be taken. In turn, this requires optimal tissue management to protect and maximize the use of this precious finite resource. Here, a group of leading thoracic pathologists recommend factors to consider for optimal tissue management. Starting from when lung cancer is first suspected, keeping predictive biomarker testing in the front of the mind should drive the development of practices and procedures that conserve tissue appropriately to support molecular characterization and treatment selection.
AB - Many patients with non-small cell lung cancer do not receive guideline-recommended, biomarker-directed therapy, despite the potential for improved clinical outcomes. Access to timely, accurate, and comprehensive molecular profiling, including targetable protein overexpression, is essential to allow fully informed treatment decisions to be taken. In turn, this requires optimal tissue management to protect and maximize the use of this precious finite resource. Here, a group of leading thoracic pathologists recommend factors to consider for optimal tissue management. Starting from when lung cancer is first suspected, keeping predictive biomarker testing in the front of the mind should drive the development of practices and procedures that conserve tissue appropriately to support molecular characterization and treatment selection.
KW - molecular characterization
KW - non-small cell lung cancer
KW - NSCLC
KW - preanalytical
KW - predictive biomarkers
KW - specimen handling
KW - tissue management
KW - tissue stewardship
UR - http://www.scopus.com/inward/record.url?scp=85176910746&partnerID=8YFLogxK
U2 - 10.1111/his.15078
DO - 10.1111/his.15078
M3 - Article
C2 - 37957137
AN - SCOPUS:85176910746
SN - 0309-0167
VL - 84
SP - 429
EP - 439
JO - Histopathology
JF - Histopathology
IS - 3
ER -
